Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
Sexual Pain among Malaysian Women Receiving Antidepressant: A Comparison between Escitalopram and Fluoxetine
1
x
$
30.00
Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects
1
x
$
0.00
Short Term Second-Generation Antidepressant Monotherapy in Acute Depressive Episodes of Bipolar II Disorder: A Systematic Review and Meta-Analysis
1
x
$
30.00
Teaching Monograph Grand Round Series: Quality-of-Life and Pharmacoeconomic Considerations of Obsessive-Compulsive Disorder
1
x
$
10.00
Sati Mazumdar, PhD: Survival Models With Time-Varying Coefficients: A Flexible Approach to the Analysis of Psychiatric Survival Data
1
x
$
30.00
Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder
1
x
$
30.00
Amy M. Kilbourne, PhD, MPH: Determinants of Complementary and Alternative Medicine Use by Patients with Bipolar Disorder
1
x
$
30.00
Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers
1
x
$
30.00
View Cart
Checkout
Home
personalized medicine
“Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers” has been added to your cart.
View cart
Sort by
Date
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers
$
30.00
Add to cart
Details
Relationship of the 1846G > A Polymorphism of the CYP2D6 Gene to the Equilibrium Concentration Levels of Haloperidol in Patients with Acute Alcoholic Hallucinosis
$
30.00
Add to cart
Details
Relationship of CYP3A4*1B Single Nucleotide Polymorphism to the Efficiency and Safety Profiles of Haloperidol in Patients Enduring Acute Alcoholic Hallucinosis
$
30.00
Add to cart
Details
Association of CYP2D6*4 Polymorphism with the Steady- State Concentration of Haloperidol in Patients with Alcohol-Induced Psychotic Disorders
$
30.00
Add to cart
Details
Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses
$
30.00
Add to cart
Details
Influence of CYP2C19*17 Genetic Polymorphism on the Steady-State Concentration of Escitalopram in Patients with Recurrent Depressive Disorder
$
30.00
Add to cart
Details
Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder
$
30.00
Add to cart
Details
Impact of the Omics-Based Biomarkers on the Mirtazapine’s Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder
$
30.00
Add to cart
Details
Impact of the Omics-Based Biomarkers on the Fluvoxamine’s Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder
$
30.00
Add to cart
Details
The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder
$
30.00
Add to cart
Details
Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder
$
30.00
Add to cart
Details
Page load link
Go to Top
